TY - JOUR
T1 - The global epidemiology of vitiligo
T2 - A systematic review and meta-analysis of the incidence and prevalence
AU - Haulrig, Morten Bahrt
AU - Al-Sofi, Rownaq
AU - Baskaran, Subisan
AU - Bergmann, Mie Siewertsen
AU - Løvendorf, Marianne
AU - Dyring-Andersen, Beatrice
AU - Skov, Lone
AU - Loft, Nikolai
N1 - Publisher Copyright:
© 2024 The Author(s). JEADV Clinical Practice published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.
PY - 2024
Y1 - 2024
N2 - Vitiligo is described with a prevalence of 0.5%−1%. Recent studies suggest an increasing prevalence, but there is a scarcity of studies that have systematically evaluated the global incidence and prevalence. We examined the incidence and the global, regional, and country-specific prevalence of vitiligo in the general population (PROSPERO: CRD42021261643). We systematically searched PubMed, EMBASE, and Web of Science. Each study was categorised in subgroups. The overall analysis comprised all studies, except for studies only examining children and adolescents. Pooled proportions were calculated with the DerSimonian-Laird method for random-effects models with 95% confidence intervals (CI). Of the 7,838 identified studies, 171 were eligible for analysis (participants n = 572,334,973). The overall incidence was 1.59 per 10,000 person-years (95% CI: 0.70−2.83). The overall prevalence was 0.40% (95% CI: 0.37−0.44); no difference was observed between females (0.50%, 95% CI: 0.36−0.66) and males (0.49%, 95% CI: 0.35−0.65). West Asia showed the highest prevalence (0.77%, 95% CI: 0.44−1.10) and East Asia the lowest (0.12%, 95% CI: 0.10−0.14). The highest country-specific prevalence was reported in Jordan (1.34%, 95% CI: 0.12−3.87) and the lowest in Sweden (0.19%, 95% CI: 0.08−0.34). Children and adolescents showed a lower prevalence (0.27%, 95% CI: 0.24−0.31) compared to adults (0.70%, 95% CI: 0.59−0.81). Questionnaire-based studies showed a higher prevalence (0.73%, 95% CI: 0.52−0.98) compared to examination-based studies (0.59%, 95% CI: 0.46−0.73) and register-based studies (0.13%, 95% CI: 0.10−0.17). The prevalence in examination-based studies increased from 0.40% (95% CI: 0.17−0.73) between 1943 and 1979 to 0.89% (95% CI: 0.68−1.13) between 2020 and 2023. Questionnaire-based studies also showed an increasing prevalence, while in register-based studies, the prevalence was continuously low. This study shows the global impact of vitiligo and how subgroup analyses influence the prevalence. The overall prevalence of vitiligo is lower than previously assumed; females and males are equally affected, and vitiligo is more common in adults.
AB - Vitiligo is described with a prevalence of 0.5%−1%. Recent studies suggest an increasing prevalence, but there is a scarcity of studies that have systematically evaluated the global incidence and prevalence. We examined the incidence and the global, regional, and country-specific prevalence of vitiligo in the general population (PROSPERO: CRD42021261643). We systematically searched PubMed, EMBASE, and Web of Science. Each study was categorised in subgroups. The overall analysis comprised all studies, except for studies only examining children and adolescents. Pooled proportions were calculated with the DerSimonian-Laird method for random-effects models with 95% confidence intervals (CI). Of the 7,838 identified studies, 171 were eligible for analysis (participants n = 572,334,973). The overall incidence was 1.59 per 10,000 person-years (95% CI: 0.70−2.83). The overall prevalence was 0.40% (95% CI: 0.37−0.44); no difference was observed between females (0.50%, 95% CI: 0.36−0.66) and males (0.49%, 95% CI: 0.35−0.65). West Asia showed the highest prevalence (0.77%, 95% CI: 0.44−1.10) and East Asia the lowest (0.12%, 95% CI: 0.10−0.14). The highest country-specific prevalence was reported in Jordan (1.34%, 95% CI: 0.12−3.87) and the lowest in Sweden (0.19%, 95% CI: 0.08−0.34). Children and adolescents showed a lower prevalence (0.27%, 95% CI: 0.24−0.31) compared to adults (0.70%, 95% CI: 0.59−0.81). Questionnaire-based studies showed a higher prevalence (0.73%, 95% CI: 0.52−0.98) compared to examination-based studies (0.59%, 95% CI: 0.46−0.73) and register-based studies (0.13%, 95% CI: 0.10−0.17). The prevalence in examination-based studies increased from 0.40% (95% CI: 0.17−0.73) between 1943 and 1979 to 0.89% (95% CI: 0.68−1.13) between 2020 and 2023. Questionnaire-based studies also showed an increasing prevalence, while in register-based studies, the prevalence was continuously low. This study shows the global impact of vitiligo and how subgroup analyses influence the prevalence. The overall prevalence of vitiligo is lower than previously assumed; females and males are equally affected, and vitiligo is more common in adults.
KW - country-specific
KW - epidemiology
KW - global
KW - regional
KW - vitiligo
U2 - 10.1002/jvc2.526
DO - 10.1002/jvc2.526
M3 - Review
AN - SCOPUS:85201698662
SN - 2768-6566
VL - 3
SP - 1410
EP - 1419
JO - JEADV Clinical Practice
JF - JEADV Clinical Practice
IS - 5
ER -